# Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

> **NCT01513460** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 773 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** NVA237 50µg once daily
- **DRUG:** Tiotropium 18µg once daily
- **DRUG:** Flu/Sal
- **DRUG:** NVA237 placebo + Tiotropium placebo.

## Key facts

- **NCT ID:** NCT01513460
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 773 (ACTUAL)
- **Last updated:** 2015-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01513460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01513460, "Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01513460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*